Gennex Laboratories Limited has intimated the stock exchanges about a scheduled Board of Directors meeting to be held on Friday, August 14, 2026 at 04:00 PM at the company's Corporate Office.
The primary agenda items for the board meeting include:
- Consideration and adoption of Unaudited Financial Statements (Standalone and Consolidated) for the quarter ended June 30, 2026 (Q1 FY27)
- Consideration of Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the quarter ended June 30, 2026
- Other business items
The disclosure references SEBI (LODR) Regulations, 2015, specifically Regulations 29(1)(a), 33 and 47.
Regarding the trading window closure, the company confirms continuation of the earlier disclosure dated June 23, 2026, which stated the trading window closure effective from July 01, 2026 pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the company's securities will reopen after 48 hours of the declaration of Unaudited Financial Results for the quarter ended June 30, 2026. This applies to all designated persons, their immediate relatives, and all connected persons covered under the company's code.
The intimation has been uploaded on the company website at www.gennexlab.com.